Literature DB >> 21532557

Belimumab.

Iñaki Sanz, Uma Yasothan, Peter Kirkpatrick.   

Abstract

Mesh:

Substances:

Year:  2011        PMID: 21532557     DOI: 10.1038/nrd3436

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  7 in total

Review 1.  Biological therapy for lupus nephritis-tribulations and trials.

Authors:  Rona M Smith; Menna R Clatworthy; David R W Jayne
Journal:  Nat Rev Rheumatol       Date:  2010-07-20       Impact factor: 20.543

Review 2.  B cells as therapeutic targets in SLE.

Authors:  Iñaki Sanz; F Eun-Hyung Lee
Journal:  Nat Rev Rheumatol       Date:  2010-06       Impact factor: 20.543

3.  BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator.

Authors:  P A Moore; O Belvedere; A Orr; K Pieri; D W LaFleur; P Feng; D Soppet; M Charters; R Gentz; D Parmelee; Y Li; O Galperina; J Giri; V Roschke; B Nardelli; J Carrell; S Sosnovtseva; W Greenfield; S M Ruben; H S Olsen; J Fikes; D M Hilbert
Journal:  Science       Date:  1999-07-09       Impact factor: 47.728

4.  Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus.

Authors:  J Zhang; V Roschke; K P Baker; Z Wang; G S Alarcón; B J Fessler; H Bastian; R P Kimberly; T Zhou
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

5.  A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Authors:  Daniel J Wallace; William Stohl; Richard A Furie; Jeffrey R Lisse; James D McKay; Joan T Merrill; Michelle A Petri; Ellen M Ginzler; W Winn Chatham; W Joseph McCune; Vivian Fernandez; Marc R Chevrier; Z John Zhong; William W Freimuth
Journal:  Arthritis Rheum       Date:  2009-09-15

6.  Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects.

Authors:  Wendy G Halpern; Patrick Lappin; Thomas Zanardi; Wendy Cai; Marta Corcoran; John Zhong; Kevin P Baker
Journal:  Toxicol Sci       Date:  2006-03-03       Impact factor: 4.849

7.  Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.

Authors:  Kevin P Baker; Bryan M Edwards; Sarah H Main; Gil H Choi; Ruth E Wager; Wendy G Halpern; Patrick B Lappin; Todd Riccobene; Donara Abramian; Les Sekut; Bonnie Sturm; Carol Poortman; Ralph R Minter; Claire L Dobson; Elizabeth Williams; Sara Carmen; Rodger Smith; Viktor Roschke; David M Hilbert; Tristan J Vaughan; Vivian R Albert
Journal:  Arthritis Rheum       Date:  2003-11
  7 in total
  13 in total

Review 1.  B-cell-depleting therapy in systemic lupus erythematosus.

Authors:  Manuel Ramos-Casals; Iñaki Sanz; Xavier Bosch; John H Stone; Munther A Khamashta
Journal:  Am J Med       Date:  2012-04       Impact factor: 4.965

2.  A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens.

Authors:  Vishal J Sindhava; Michael A Oropallo; Krishna Moody; Martin Naradikian; Lauren E Higdon; Lin Zhou; Arpita Myles; Nathaniel Green; Kerstin Nündel; William Stohl; Amanda M Schmidt; Wei Cao; Stephanie Dorta-Estremera; Taku Kambayashi; Ann Marshak-Rothstein; Michael P Cancro
Journal:  J Clin Invest       Date:  2017-03-27       Impact factor: 14.808

Review 3.  Role of type I interferons in the activation of autoreactive B cells.

Authors:  Kerstin Kiefer; Michael A Oropallo; Michael P Cancro; Ann Marshak-Rothstein
Journal:  Immunol Cell Biol       Date:  2012-03-20       Impact factor: 5.126

Review 4.  Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.

Authors:  Michael Croft; Richard M Siegel
Journal:  Nat Rev Rheumatol       Date:  2017-03-09       Impact factor: 20.543

5.  Beyond transitional selection: New roles for BLyS in peripheral tolerance.

Authors:  Michael A Oropallo; Kerstin Kiefer; Ann Marshak-Rothstein; Michael P Cancro
Journal:  Drug Dev Res       Date:  2011-12       Impact factor: 4.360

6.  The Expression of BAFF Is Controlled by IRF Transcription Factors.

Authors:  Maria Sjöstrand; Alina Johansson; Lara Aqrawi; Tomas Olsson; Marie Wahren-Herlenius; Alexander Espinosa
Journal:  J Immunol       Date:  2015-11-20       Impact factor: 5.422

7.  A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans.

Authors:  Konstantinos Biliouris; Ivan Nestorov; Himanshu Naik; David Dai; Guangqing Xiao; Qin Wang; Alex Pellerin; Dania Rabah; Lawrence J Lesko; Mirjam N Trame
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-10-30       Impact factor: 2.745

8.  New treatment options for lupus - a focus on belimumab.

Authors:  Laurent Chiche; Noémie Jourde; Guillemette Thomas; Nathalie Bardin; Charleric Bornet; Albert Darque; Julien Mancini
Journal:  Ther Clin Risk Manag       Date:  2012-01-26       Impact factor: 2.423

Review 9.  Clinical translation of immunomodulatory therapeutics.

Authors:  Amanda Nash; Samira Aghlara-Fotovat; Andrea Hernandez; Christopher Scull; Omid Veiseh
Journal:  Adv Drug Deliv Rev       Date:  2021-07-27       Impact factor: 17.873

Review 10.  Idiopathic Inflammatory Myopathies: Clinical Approach and Management.

Authors:  Asma Malik; Ghazala Hayat; Junaid S Kalia; Miguel A Guzman
Journal:  Front Neurol       Date:  2016-05-20       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.